peoplePerson
Shahneen Sandhu
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
Shahneen Sandhu leads combination trials of 177Lu-PSMA with androgen-receptor pathway inhibitors and immunotherapy (PRINCE, UpFrontPSMA), and contributes to melanoma and early-phase research.
Role
Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac
Institution
Specialisms
Prostate cancerTheranosticsMelanomaEarly-phase trials
| Title | Journal | Year |
|---|---|---|
| Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (UpFrontPSMA) | Lancet Oncology | 2024 |